Novavax Archives | Page 4 of 6

Home / Posts tagged Novavax (Page 4)

Novavax Announces Publication of Phase 1 Data for COVID-19 Vaccine Candidate in The New England Journal of Medicine

GAITHERSBURG, Md., Sept. 2 (Korea Bizwire) — Novavax, Inc. (Nasdaq: NVAX), a late stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced the publication in The New England Journal of Medicine of Phase 1 data from its Phase 1/2 clinical trial of NVX‑CoV2373, its COVID‑19 vaccine candidate adjuvanted with Matrix‑M™, in healthy adults 18-59 [...]

Novavax and Canada Reach Agreement in Principle to Acquire Novavax’ COVID-19 Vaccine

GAITHERSBURG, Md., Aug. 31 (Korea Bizwire) — Novavax, Inc. (Nasdaq: NVAX), a late stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced it has reached an agreement in principle with the Government of Canada to supply up to 76 million doses of NVX-CoV2373, Novavax’ COVID-19 vaccine. “We are pleased to work with [...]

Novavax Initiates Phase 2 Portion of Phase 1/2 Clinical Trial of COVID-19 Vaccine

GAITHERSBURG, Md., Aug. 24 (Korea Bizwire) — Novavax, Inc. (Nasdaq: NVAX), a late stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that the first volunteers have been enrolled in the Phase 2 portion of its ongoing clinical trial to evaluate the immunogenicity and safety of NVX-CoV2373, Novavax’ COVID-19 vaccine candidate. The [...]

Novavax Initiates Efficacy Trial of COVID-19 Vaccine in South Africa

GAITHERSBURG, Md., Aug. 17 (Korea Bizwire) — Novavax, Inc. (NASDAQ: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced the beginning of a Phase 2b clinical trial in South Africa to evaluate the efficacy of NVX-CoV2373, Novavax’ COVID-19 vaccine candidate. Dr. Shabir Madhi, Professor of Vaccinology at Wits University, will [...]

Novavax and UK Government Announce Collaboration and Purchase Agreement for Novavax’ COVID-19 Vaccine Candidate

GAITHERSBURG, Md., Aug. 14 (Korea Bizwire) — Novavax, Inc. (Nasdaq: NVAX), a late stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced it has signed a Heads of Terms (Term Sheet) with the Government of the United Kingdom (UK) for the purchase of 60 million doses of NVX-CoV2373, Novavax’ COVID-19 vaccine, and [...]

Novavax and SK bioscience Announce Collaboration for Novavax’ COVID-19 Vaccine Candidate

GAITHERSBURG, Md. and SEOUL, South Korea, Aug. 13 (Korea Bizwire) — Novavax, Inc. (Nasdaq: NVAX), a late stage biotechnology company developing next-generation vaccines for serious infectious diseases, and SK bioscience, a vaccine business subsidiary of SK Group, today announced a development and supply agreement for the antigen component of NVX-CoV2373, Novavax’ COVID-19 vaccine candidate, for [...]

Novavax Reports Second Quarter 2020 Financial and Operational Results

GAITHERSBURG, Md., Aug. 10 (Korea Bizwire) — Novavax, Inc. (NASDAQ: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced its financial results and operational highlights for the second quarter ended June 30, 2020. “Novavax’ unprecedented development activities for NVX-CoV2373 and progress continued through the second quarter,” said Stanley C. Erck, [...]

Novavax and Takeda Announce Collaboration for Novavax’ COVID-19 Vaccine Candidate in Japan

GAITHERSBURG, Md. and OSAKA, Japan, Aug. 7 (Korea Bizwire) — Novavax, Inc. (Nasdaq: NVAX), a late stage biotechnology company developing next-generation vaccines for serious infectious diseases, and Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK), today announced a partnership for the development, manufacturing and commercialization of NVX‑CoV2373, Novavax’ COVID‑19 vaccine candidate, in Japan. NVX‑CoV2373 is a stable, prefusion [...]

Novavax and Serum Institute of India Announce Development and Commercial Collaboration

GAITHERSBURG, Md., Aug. 6 (Korea Bizwire) — Novavax, Inc. (Nasdaq: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced a license agreement with Serum Institute of India Private Limited (SIIPL) for the development and commercialization of NVX‑CoV2373, Novavax’ COVID‑19 vaccine candidate, in low- and middle-income countries (LMIC) and India. This [...]

Novavax to Host Conference Call to Discuss Second Quarter Financial and Operating Results on August 10, 2020

GAITHERSBURG, Md., Aug. 6 (Korea Bizwire) — Novavax, Inc. (Nasdaq: NVAX), a late stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced it will report its second quarter 2020 financial and operating results following the close of U.S. financial markets on Monday, August 10, 2020. Conference call details are as follows: Date: [...]